|
Synonyms: capromab pendetide | CYT-351 | CYT-356 | Indium In 111 capromab | ProstaScint®
capromab is an approved drug (FDA (1996))
Compound class:
Antibody
Comment: Used as an imaging agent (ProstaScint) by labelling with the radionuclide Indium-111 (using capromab pendetide, where the pendetide is the chelating agent for the radiolabel).
|
| Bioactivity Comments |
| We have been unable to find affinity data for this antibody from any open access source. |
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Targets where the ligand is described in the comment field | |
| Target | Comment |
| Folate hydrolase (prostate-specific membrane antigen) 1 | Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate (L-glutamic acid). In the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up-regulated in cancerous tissue. A tagged version of the antibody capromab has been used for imaging purposes. |
| Ligand mentioned in the following text fields |
| M28: Aminopeptidase Y comments |
